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Abstract
Outcome measures used for the clinical evaluation of patients with acute heart failure differ between studies and may neither
adequately address the characteristic presenting symptoms and signs nor reﬂect the pathophysiological processes involved. In-
hospital worsening of heart failure (WHF) is associated with poor outcomes and thus a potential endpoint conveying clinically
meaningful prognostic information.
Current deﬁnitions of WHF are based on the combination of worsening symptoms and signs and the intensiﬁcation of treat-
ment during admission. Deﬁnitions vary across studies and do not fully account for baseline therapy or circumstances in which
there is failure to respond to treatment. Further, there are limited data to inform healthcare professionals as to which patients
are most at risk of developing in-hospital WHF.
In this opinion piece, we review the deﬁnitions for WHF used in recent and ongoing clinical trials and propose a novel
deﬁnition, which captures failure to respond to treatment as well as clinical worsening (deterioration of symptoms and signs)
of the patient’s condition. Such a deﬁnition, applied consistently across studies, would help clarify the characteristics of
patients likely to develop in-hospital WHF, allow comparative assessments of the effectiveness of interventions, and help
guide appropriate patient management in order to improve outcomes.
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Introduction
Chronic heart failure (HF) is frequently punctuated by epi-
sodes of decompensation, often necessitating hospitalization
[acute HF (AHF)].1 Frequent HF-related hospitalizations are a
considerable burden for patients, carers, and healthcare pro-
viders.2,3 Furthermore, patients hospitalized with AHF have a
poor prognosis, with high rates of in-hospital and post-
discharge mortality, and a high risk of early readmission.4
The early identiﬁcation of patients with AHF at high risk of
poor outcomes may be an important step in improving prog-
nosis. To assess therapeutic interventions, robust markers of
disease severity that reﬂect AHF pathophysiology and which
are related to longer term outcomes would be beneﬁcial.4
Biomarkers, such as N-terminal pro-B-type natriuretic peptide
(NT-proBNP), are likely to be useful in this regard; high levels
are associated with poor prognosis, and thus interventions
guided by changes in N terminal pro brain natriuretic peptide
may be helpful.5–9 Trials designed with sufﬁcient power are
needed to conﬁrm the beneﬁts of this approach.10 In addition
to biomarkers, in-hospital worsening HF (in-hospital WHF)
has been proposed as a potentially useful endpoint for iden-
tifying high-risk patients with AHF.11
Endpoints should be consistent, reproducible, sensitive
(that is, responsive to change in clinical state), and clinically
meaningful, to allow comparisons across studies and be use-
ful to physicians. However, to date, in-hospital WHF has been
deﬁned in multiple ways, including (i) a failure to respond to
standard therapy (although ‘standard therapy’ is not always
well deﬁned);12,13 (ii) a gradual deterioration of AHF despite
therapy;11 and (iii) the abrupt occurrence of WHF events,
such as the development of pulmonary oedema.11–13 Table
1 shows the varying deﬁnitions of WHF used in a number of
intervention trials in AHF.11–21 Studies deﬁning in-hospital
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WHF as worsening symptoms and signs of HF and a need for
additional intravenous (i.v.) or mechanical therapy suggest
that 10–25% of patients admitted with AHF develop
WHF,11,14 although incidence rates of up to 42% have been
reported.4,14 Conversely, results from the Acute Study of Clin-
ical Effectiveness of Nesiritide in Decompensated Heart Fail-
ure (ASCEND-HF), the largest trial of patients with AHF to
date (n = 7141), showed that only approximately 5% of pa-
tients experienced in-hospital WHF,20 which perhaps reﬂects
the more rigorous deﬁnition used in the study [≥1 sign, symp-
tom, or radiological evidence of new, persistent, or worsening
AHF requiring addition of a new i.v. therapy (inotrope or
vasodilator) or mechanical support during index hospitaliza-
tion] (Table 1).
Although deﬁnitions vary across trials, the occurrence of
in-hospital WHF consistently predicts poorer outcomes in pa-
tients with AHF and is associated with increased healthcare
utilization.11,12,14,15,17,19,22 These studies have raised interest
in the validity of in-hospital WHF as a useful endpoint for
evaluating new AHF therapies and in clinical practice.4,11 If
the concept is validated, reducing the occurrence of in-
hospital WHF might itself become a worthwhile treatment
target; however, as authors, we had some scepticism as to
the clinical utility of this outcome in the absence of a
Table 1 Comparison of in-hospital worsening heart failure (WHF) deﬁnitions and outcomes in clinical studies
Study Deﬁnition
Endpoints associated with the
occurrence of in-hospital WHF
VERITAS12,13 (Tezosentan) WHF occurring during the index hospitalization was deﬁned as
development of pulmonary oedema, cardiogenic shock, or other
evidence of WHF, or failure of the patient’s HF condition to improve
with treatment (treatment failure), requiring the initiation, re-
institution, or increase in i.v. therapy for HF and/or the
implementation of mechanical circulatory or ventilator support and/or
the use of ultraﬁltration, haemoﬁltration, or haemodialysis within
7 days post-randomization
• Longer length of hospitalization
• Greater risk of 30-day HF
readmission or death
Tel-Aviv medical centre
study14 (Standard of care)
Unresolved or recurrent signs/symptoms of HF that required an increase
in or institution of i.v. HF-speciﬁc therapy, or mechanical ventilatory or
circulatory support within 7 days of admission
• Greater 6 month mortality
PROTECT pilot11
(Rolofylline)
(i) Acute event of pulmonary congestion or oedema during the
time since the previous evaluation and/or
(ii) Worsening in investigator-reported and/or patient-reported
symptoms and signs of AHF since the previous evaluation, and
(iii) (i) and/or (ii) occurred concomitantly with instituting/increasing
the dose of i.v. therapy or mechanical support
• Slower resolution of dyspnoea
• Longer length of hospitalization
• Greater 60-day mortality
• Higher CV or renal readmission
rates
Pre-RELAX-AHF15
(Serelaxin)
WHF signs/symptoms necessitating intensiﬁcation or re-institution of
i.v. or mechanical HF treatment from admission to Day 5
• Longer length of hospitalization
• Reduced number of days alive
out of hospital up to Day 60
• Greater 180-day CV mortality
DOSE16,21 (Furosemide) Worsening or persistent HF requiring rescue therapy (loop diuretic,
thiazide, i.v. vasoactive agents, ultraﬁltration, or mechanical or
respiratory support) from randomization to Day 3a
• Persistent or worsening HF up
to Day 3
RELAX-AHF17 (Serelaxin) WHF signs/symptoms necessitating intensiﬁcation or re-institution of
i.v. or mechanical HF treatment from admission to Day 5
• Greater 180-day all-cause
mortality
ROSE-AHF18 (Low-dose
dopamine, low-dose
nesiritide)
Worsening or persistent HF requiring rescue therapy (i.v. vasoactive
agents, ultraﬁltration, or mechanical or respiratory support)
• Persistent or worsening HF up
to Day 3
ADHERE registry19
(Standard of care)
Need for escalation of therapy (inotropic medications or i.v.
vasodilator) >12 h after hospital presentation, transfer to the
intensive care unit, or advanced medical therapy after the ﬁrst
inpatient day
• Greater mortality at 30 days
and 1 year
• Greater all-cause readmission
at 30 days and 1 year
• Greater Medicare payments at
30 days and 1 year
ASCEND-HF20 (Nesiritide) Presence of ≥1 symptom or sign of new, persistent, or worsening acute
HF requiring additional i.v. therapy (inotropic or vasodilator) or
mechanical support during hospitalization (early WHF)
• Greater all-cause mortality or
HF rehospitalization at 30 days
• Greater all-cause mortality at
30 or 180 days
ADHERE, Acute Decompensated Heart Failure National Registry; AHF, acute heart failure; ASCEND-HF, Acute Study of Clinical Effectiveness
of Nesiritide in Decompensated Heart Failure; CV, cardiovascular; DOSE, Diuretic Optimization Strategies Evaluation; HF, heart failure; i.v.,
intravenous; PROTECT, Effects of Rolofylline, a New Adenosine A1 Receptor Antagonist on Symptoms, Renal Function, and Outcomes in
Patients with Acute Heart Failure; RELAX-AHF, serelaxin in acute heart failure; ROSE-AHF, Renal Optimization Strategies Evaluation in
Acute Heart Failure; VERITAS, Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies; WHF, worsening
heart failure.
aPlease refer to supplementary material available online at http://www.nejm.org/action/showSupplements?doi=10.1056%
2FNEJMoa1005419&viewType=Popup&viewClass=Suppl.
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standard deﬁnition. Therefore, in this review, which gives our
opinion rather than being data-driven, we critically appraise
the current criteria used to deﬁne in-hospital WHF and iden-
tify areas of strength and weakness. We propose a novel,
clinically relevant deﬁnition that includes both failure to re-
spond to treatment [poorly responsive HF (PRHF)] and clinical
worsening during hospital admission. We believe this new
deﬁnition will help to assess the effectiveness of interven-
tions in AHF and facilitate comparisons between them.
What is ‘in-hospital worsening heart
failure’ and how has the deﬁnition of
the endpoint evolved?
One challenge with establishing a consistent deﬁnition of ‘in-
hospital WHF’ is that patients present in different ways, and
thus, ‘worsening’ may vary with clinical context. Clinical trials
often emphasize inclusion criteria that depend on classiﬁca-
tions such as ‘decompensation of chronic HF’ or ‘de novo
AHF’, but the emergency physician places much greater em-
phasis on the symptoms and signs with which the patient
presents. Characterizing an AHF episode is important for both
in-hospital and post-hospital patient management, as it de-
termines which patients are at higher risk of poorer out-
comes and, consequently, helps guide therapy. However, full
characterization at admission is challenging because of multi-
ple and overlapping clinical presentations.23,24
The deﬁnition of any proposed new clinical endpoint
should be precise and, to date, in-hospital WHF has neither
been tightly nor consistently deﬁned.11,14,19 Some deﬁni-
tions of in-hospital WHF are not strictly ‘worsening’. For ex-
ample, if a patient simply responds slowly to i.v. diuretic,
leading to an increase in the dosage, can that really be de-
ﬁned as worsening? Further, if a patient simply fails to re-
spond to diuretic and remains oedematous, that is surely
‘failure to respond’ rather than ‘worsening’. Even when
such concepts have been reﬂected as part of the inclusion
criteria for a clinical trial, all is not as it seems. For exam-
ple, the inclusion requirements for the Cardiorenal Rescue
Study in Acute Decompensated Heart Failure (CARRESS-
HF) required that patients have worsening renal function
and persistent oedema, implying that they either had
WHF or HF that was failing to respond.25 However, the pa-
tients allocated to conventional therapy in the trial subse-
quently improved, suggesting that they were neither
failing to respond nor worsening.25
In 2010, a standard deﬁnition for in-hospital WHF was pro-
posed by Cotter et al., incorporating both worsening symp-
toms and signs of HF and the need to institute or increase
speciﬁc HF-related i.v. or mechanical therapy.11 In-hospital
WHF was deemed to have occurred if the following were ob-
served: (i) acute pulmonary congestion or oedema during the
time since the previous evaluation; and/or (ii) worsening in
investigator-reported and/or patient-reported symptoms
and signs of AHF since the previous evaluation; and (iii) the
events identiﬁed in (i) and/or (ii) occurred concomitantly with
instituting or increasing the dose of i.v. therapy or mechanical
support (ventilatory or circulatory).11 This proposal is largely
consistent with endpoints used in several clinical studies
(Table 1).
The growing awareness of in-hospital WHF as a clinical
endpoint has been strengthened by its inclusion in a
European Society of Cardiology consensus document on clin-
ical trial endpoints for HF.26 The document highlights that (i)
WHF during the index hospitalization may be used as a com-
ponent of the primary composite endpoint; (ii) in-hospital
WHF may capture important, non-fatal events occurring prior
to discharge; (iii) consistent capturing of in-hospital WHF
events across trial sites is important; and (iv) speciﬁc criteria
for the diagnosis must be pre-deﬁned.26
In line with these recommendations, several ongoing and
recently completed AHF trials include in-hospital WHF as a
prospectively deﬁned endpoint (Table 227–35); this is likely
to contribute to its validation and increase physician familiar-
ity with it as a clinical concept, as well as provide data on the
effectiveness of interventions in preventing WHF.
The deﬁnition of in-hospital WHF in current and recently
completed trials is still not uniform. For example, in the
Serelaxin in AHF trials (RELAX-AHF-2, RELAX-AHF-EU, and
RELAX-AHF-ASIA),27–29 in-hospital WHF is deﬁned as worsen-
ing signs and/or symptoms of HF between admission and
Day 5 that require intensiﬁcation of i.v. therapy for HF or me-
chanical ventilatory, renal, or circulatory support (Data on
File, Novartis Pharma AG). In-hospital WHF in the TRial of
Ularitide’s Efﬁcacy and safety in patients with Acute Heart
Failure (TRUE-AHF), ularitide vs. placebo is deﬁned differ-
ently, requiring an intervention (initiation or intensiﬁcation
of i.v. therapy, circulatory or ventilatory mechanical support,
surgical intervention, ultraﬁltration, haemoﬁltration, or dialy-
sis) for persistent or worsening HF up to 48 h after the start of
study drug.30,31
What is the clinical relevance of
in-hospital worsening heart failure?
Our current ability to predict the occurrence of in-hospital
WHF is limited. WHF may be more likely in the context
of poor renal function on admission, being associated with
low renal perfusion pressure and marked neurohormonal
activation.12 Measures indicative of worse haemodynamic
function on admission and 6 h later, such as decreased car-
diac power output and increased mean arterial pressure,
are associated with a higher rate of in-hospital WHF by
Day 7.4 Other admission characteristics predictive of
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in-hospital WHF include increased respiratory rate (which
may indicate pulmonary oedema), hyponatraemia, low oxy-
gen saturation, high troponin levels, and the need for
more aggressive management, such as mechanical ventila-
tion, i.v. diuretics, and inotropes.12,14,15 There is consistent
evidence from several studies that in-hospital WHF is
associated with adverse prognosis—the study deﬁnitions
of in-hospital WHF used, together with key outcome data,
are shown in Table 1.
Value of Endothelin Receptor Inhibition with
Tezosentan in Acute Heart Failure Studies
In Value of Endothelin Receptor Inhibition with Tezosentan
in Acute Heart Failure Studies (VERITAS) (n = 1347), the in-
cidence of WHF within 7 days of admission was one of two
co-primary endpoints, combined with death. WHF could oc-
cur during the index hospitalization (in-hospital WHF) or
post-discharge (re-hospitalization for WHF). WHF by Day 7
during the index admission occurred in 26% of patients
and, after adjustment for baseline characteristics, was asso-
ciated with a mean increase in length of hospital stay (LOS)
of 4.33 days (P < 0.0001) and a hazard ratio (HR) for
30-day HF readmission or death of 2.43 (P < 0.0001;
Figure 1A12). Any WHF within 7 days (during the index hos-
pitalization or a re-hospitalization) was associated with an
HR for 90-day mortality of 2.57 (P < 0.0001).12,13 However,
in-hospital WHF was only modestly inﬂuenced by patients’
baseline characteristics (such as severity of HF and end-
organ impairment) during the ﬁrst day of admission,
underlining the difﬁculty physicians encounter in early iden-
tiﬁcation of patients at risk of poor outcomes. Cotter et al.
suggest that current clinical assessments may not be sufﬁ-
ciently tailored to capture patients at risk of developing
in-hospital WHF.12
Tel-Aviv medical centre study
Weatherley et al. assessed the association of in-hospital
WHF with prognosis over 6 month follow-up in 337 patients
admitted with AHF to a regional medical centre in Tel Aviv.14
The 29% of patients who experienced in-hospital WHF during
the early stages of admission had higher 30-day (17.2% vs.
3.4%) and 6-month mortality rates (21.2% vs. 7.1%; Figure
1B14) compared with those with no in-hospital WHF.14 Factors
associated with short-term adverse outcomes in AHF, such as
systolic blood pressure, were not predictive of in-hospital
WHF. The authors concluded that WHF is an independent pre-
dictor of adverse outcomes.14 However, caution is needed, as
the results and conclusions derived from this study could be at-
tributed to the imprecise deﬁnition used for in-hospital WHF
(Table 1). For example, if a patient did not respond to 10 mg
daily of furosemide and the dosage was increased to 80 mg
twice daily, then the patient would have had ‘in-hospital
WHF’.We suggest that it is important for anydeﬁnition to allow
for failure to respond to, or the need to augment, standard
therapy; however, standard therapy should be appropriate be-
fore intensiﬁcation can genuinely be regarded as an adverse
event.
The Effects of Rolofylline, a New Adenosine A1
Receptor Antagonist on Symptoms, Renal
Function, and Outcomes in Patients with Acute
Heart Failure study
The investigators in the Effects of Rolofylline, a New Adeno-
sine A1 Receptor Antagonist on Symptoms, Renal Function,
and Outcomes in Patients with Acute Heart Failure study
(PROTECT pilot study) recorded prospectively the symptoms
and signs of HF and diuretic administration in patients with
AHF and renal impairment for 7 days following hospital
Table 2 In-hospital worsening heart failure (WHF) deﬁnitions in ongoing and recently completed acute heart failure clinical trials
Trial Deﬁnition
RELAX-AHF-2;27 RELAX-AHF-EU;28
RELAX-AHF-ASIA29 (Data on File,
Novartis Pharma AG) (Serelaxin)
Worsening signs and/or symptoms of HF through Day 5 post-randomization requiring
intensiﬁcation of i.v. therapy for HF or mechanical ventilatory, renal, or circulatory support
Such treatment can include the institution or up-titration of i.v. diuretic, i.v. nitrates, or any other
i.v. medication for HF, or institution of mechanical support such as mechanical ventilation,
ultraﬁltration, haemodialysis, intra-aortic balloon pump, or ventricular assist device.
TRUE-AHF30,31 (Ularitide) Persistent or WHF requiring an intervention (initiation or intensiﬁcation of i.v. therapy, circulatory
or ventilatory mechanical support, surgical intervention, ultraﬁltration, haemoﬁltration, or
dialysis) within 48 h post-start of study drug
BLAST-AHF32,33,35 (TRV027a) WHF requiring intensiﬁcation of therapy including i.v. diuretic, i.v. nitrates, or other medications
for HF, or institution of mechanical or ventilator support
ATOMIC-AHF34 (Omecamtiv
mecarbil)
Worsening symptoms or signs of HF necessitating initiation, reinstitution, or intensiﬁcation of i.v.
or mechanical HF treatment
BLAST-AHF, Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure; HF, heart failure; i.v., intravenous; RELAX-AHF,
serelaxin in acute heart failure; TRUE-AHF, TRial of Ularitide’s Efﬁcacy and safety in patients with Acute Heart Failure; WHF, worsening
heart failure.
aA novel biased ligand of the angiotensin-2 type 1 receptor.
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admission. In a post hoc analysis, patients were categorized
into three groups: (i) physician-determined WHF (n = 29);
(ii) increased i.v. diuretic therapy without physician-
determined WHF (n = 61); (iii) neither (i) nor (ii) (n = 211).11
Physician-determined WHF was associated with slower
resolution of dyspnoea (Figure 211) and longer LOS (13.8 vs.
10.5 vs. 9.3 days in Groups 1, 2, and 3; P < 0.05 for Groups
2 or 3 vs. Group 1). Death and cardiovascular (CV) or renal re-
admission rates at 60 days were also higher in the physician-
determined WHF group (49.7% vs. 37.3% vs. 19.5% in Groups
1, 2, and 3, respectively). The authors concluded that
physician-determined in-hospital WHF may be an indicator
of short-term risk and lack of treatment efﬁcacy in AHF.11
However, if failure of breathlessness to resolve rapidly leads
the physician to deﬁne the patient as ‘worsening,’ it is then
scarcely surprising that WHF predicts ‘slower resolution of
dyspnoea’ and a longer hospitalization.
A recent post hoc analysis of data from PROTECT assessed
the impact of time of WHF occurrence on patient outcomes.
In total, 12.7% of patients experienced WHF, of whom 47.9%
experienced WHF ‘early’ (Days 2–3) and 52.1% experienced
WHF ‘late’ (Days 4–7). In-hospital WHF was associated with
a trend towards greater 60-day mortality or CV/renal hospi-
talization [HR 1.26; 95% conﬁdence interval (CI): 0.99–1.60;
P = 0.063] and greater 180-day mortality (HR 1.77; 95% CI:
1.33–2.34; P < 0.001) compared with patients who did not
experience WHF. However, there was no association between
the time in-hospital WHF occurred and patient outcomes.36
Figure 1 In-hospital worsening heart failure (WHF) and reported outcomes in recent clinical trials. Kaplan–Meier estimates of (A) cumulative risk of
death or heart failure (HF) hospitalization through Day 30 by occurrence of WHF through Day 7, shown with 95% conﬁdence intervals and number
of subjects at risk in VERITAS.12 (B) Survival for patients with and without WHF within 7 days of admission.14 (C) Risk of all-cause mortality through
Day 180 shown with number of subjects at risk in RELAX-AHF.17 (D) Observed all-cause mortality up to 1 year post-index hospitalization in ADHERE.19
ADHERE, Acute Decompensated Heart Failure National Registry; HR, hazard ratio; RELAX-AHF, serelaxin in acute heart failure; VERITAS, Value of
Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies. Figure (A) reproduced with permission from Cotter et al.11; Figure
(B) reproduced with permission from Weatherley et al.14; Figure (C) reproduced with permission from Metra et al.17; Figure (D) reproduced with per-
mission from DeVore et al.19
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The Serelaxin in Acute Heart Failure studies
In the preliminary Serelaxin in Acute Heart Failure study (Pre-
RELAX-AHF) (n = 232), approximately 16% of patients experi-
enced in-hospital WHF by Day 5, which was associated with
longer LOS (15.9 vs. 10.1 days; P = 0.0006), reduced number
of days alive and out of hospital up to Day 60 (36.2 vs.
48.7 days; P = 0.0004), and higher 180-day CV mortality
(16.5% vs. 3.0%; P = 0.0045) compared with patients who
did not experience WHF by Day 5.15 A post hoc analysis of
RELAX-AHF (n = 1161) showed that patients who developed
in-hospital WHF by Day 5 (~10% of total population) had
greater 180-day all-cause mortality compared with patients
who did not (Figure 1C).17
Pooled analysis of the PROTECT and RELAX-AHF
studies
In a pooled analysis using data from 3691 patients in the PRO-
TECT pilot, PROTECT, Pre-RELAX-AHF, and RELAX-AHF studies,
12.4% of patients died or experienced in-hospital WHF by
Day 5. After multivariable adjustment (which excluded the pa-
tients who died by Day 5), patients with, rather than without,
in-hospital WHF had a mean increase in LOS of 5.2 days and
increased risks of 180-day all-cause mortality and the compos-
ite endpoint of 60-day HF re-hospitalization/renal failure hos-
pitalization or CV death (all P < 0.0001).37
The Acute Decompensated Heart Failure National
Registry
A retrospective, observational analysis of data from the
Acute Decompensated Heart Failure National Registry
(ADHERE) examined outcomes for patients with in-hospital
WHF (n = 7032), deﬁned as the need for escalation of ther-
apy at least 12 h after hospital presentation. Patients with
WHF were compared with (i) those with an uncomplicated
hospital course (n = 41 334) and (ii) those with a ‘compli-
cated hospital presentation’ in whom initiation or escalation
of therapy was required within 12 h, or admission to the
intensive care unit or advanced medical therapy was re-
quired on the ﬁrst day (n = 15 361).19 Patients with in-
hospital WHF had a higher mortality rate (Figure 1D19), a
higher all-cause readmission rate, and higher Medicare
payments at 30 days and 1 year than patients with either
an uncomplicated hospital course or a complicated presen-
tation (all P < 0.001). Interestingly, some patients with a
complicated presentation would have met the deﬁnition
for in-hospital WHF in other studies yet had better out-
comes than those deﬁned as having in-hospital WHF in
the ADHERE analysis. These data suggest that the timing
of the event deﬁning WHF may be important. However,
the authors were unable to distinguish between escalation
of therapy due to in-hospital WHF and treatment of a
concomitant condition, such as pneumonia, and thus, AD-
HERE might have captured patients with clinical presenta-
tions unrelated to HF.19
Figure 2 Change in dyspnoea score by study day in patients with/without in-hospital worsening heart failure (WHF). Mean patient-reported
dyspnoea change score over time on a Likert scale, in patients with and without in-hospital WHF.11 i.v., intravenous. Figure reproduced with
permission: Cotter G et al.11. © 2009 Karger AG, Basel.
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The Acute Study of Clinical Effectiveness of
Nesiritide in Decompensated Heart Failure
A retrospective analysis of the ASCEND-HF trial (n = 7141)
assessed the prevalence, clinical characteristics, and out-
comes of patients with in-hospital WHF (deﬁned as ≥1 sign
or symptom of new, persistent, or worsening acute HF requir-
ing addition of therapy or mechanical support).20 Overall,
WHF occurred in 5% of patients in the study. Patients who ex-
perienced in-hospital WHF had higher 30-day mortality
(29.7% vs. 2.5%), higher 30-day mortality or HF re-
hospitalization (42.7% vs. 8.1%), and higher 180-day mortality
(41.5% vs. 11.3%) rates than patients who did not develop
WHF (all P < 0.0001). Similar to the post hoc analysis of the
PROTECT study,36 patients with WHF had poorer outcomes ir-
respective of whether WHF occurred ‘early’ (Days 1–3) or
‘late’ (Day 4–discharge).20
Efﬁcacy of Vasopressin Antagonism in Heart
Failure: outcome Study with Tolvaptan
A post hoc analysis of data from the Efﬁcacy of Vasopressin
Antagonism in Heart Failure: Outcome Study with Tolvaptan
(EVEREST) trial (n = 3214) suggested that higher average daily
loop diuretic dosage (>120 mg) during hospitalization was
associated with worse clinical status, all-cause mortality,
and increased risk of in-hospital WHF compared with patients
receiving lower average daily dosages of loop diuretics
(61–120 and 60 mg).38 It is possible that persistent HF
requiring high-dose diuretics reﬂects diuretic resistance
rather than WHF.
Efﬁcacy and safety of ularitide for the treatment of
acute decompensated heart failure
The TRUE-AHF trial assessed ularitide vs. placebo in pa-
tients with AHF (n = 2157).30,31,39 The primary endpoints
were CV mortality and a hierarchical clinical composite
endpoint, which included persistent or WHF requiring an
intervention (initiation or intensiﬁcation of i.v. therapy, cir-
culatory or ventilatory mechanical support, surgical inter-
vention, ultraﬁltration, haemoﬁltration, or dialysis) within
48 h post-start of study drug.30,31,39 Ularitide was associ-
ated with fewer in-hospital worsening HF events at 48 h,
compared with placebo (55 vs. 87; P = 0.005).39 At
15 month mean follow-up, there was no difference in CV
mortality between ularitide and placebo (HR 1.03; 95% CI:
0.85–1.25).39 There were also no statistically signiﬁcant dif-
ferences between ularitide and placebo in 30-day
readmissions for HF, death from any cause, or CV hospital-
ization at 6 months.39,40
Future directions: towards an agreed
deﬁnition of in-hospital worsening
heart failure and its implementation in
clinical practice
The in-hospital WHF deﬁnitions used in trials to date have
combined several elements: slow response to treatment, fail-
ure to respond to treatment, and actual worsening despite
treatment. Because of varying trial inclusion criteria, there
is a lack of precision in understanding who the patients are,
how severe their ﬂuid retention was at inclusion, and how
these patients responded to treatment. For example, there
may well be a difference between a patient ‘failing to re-
spond’ when they start with modest ankle oedema vs.
anasarca.
For the clinical concept of in-hospital WHF to be helpful, it
must apply to a recognizable group of patients who are re-
ceiving an appropriate level of baseline therapy. We suggest
that it most readily applies to patients presenting predomi-
nantly with ﬂuid retention; those patients presenting with
acute pulmonary oedema have a life-threatening medical
emergency that already requires intensive therapy, and the
notion of ‘worsening’ in this circumstance is difﬁcult to deﬁne
with precision. Furthermore, it is not surprising that patients
who fail to respond to treatment (or deteriorate despite
treatment) are likely to spend longer in hospital and have a
worse prognosis, thus leading to a circular argument. There
should also be some consequence to arriving at a clinical di-
agnosis of in-hospital WHF: what are the implications for
therapy? Can we, and should we, do anything differently
for these patients? Finally, it may be prudent to consider
whether adjudication of in-hospital WHF events in clinical
trials should be blinded to help delineate those with and
without events in a systematic and fair way.
We propose that in-hospital WHF should encompass the
notion of failing to respond, as well as clinical worsening and
be termed ‘poorly responsive’ HF. The concept of PRHF can
be applied to patients meeting the following criteria: (i) evi-
dence of sufﬁciently severe ﬂuid retention that, in the treating
physician’s view, the patient requires i.v. diuretic therapy and
(ii) the patient is already receiving treatment with reasonable
baseline therapy (e.g. i.v. furosemide 80 mg twice daily bolus
or 10 mg/h infusion for at least 24 h). In patients meeting both
these criteria, PRHF can then be deﬁned as either the failure to
have a clinically meaningful, or perhaps even speciﬁed (for
example, 1.5 L of ﬂuid in 24 h), net loss of ﬂuid and/or the need
(in the treating physician’s opinion) for intensiﬁcation of di-
uretic therapy, ventilatory support, or mechanical support.
Further research is needed to determine the beneﬁts of
utilizing PRHF, including robust testing in large datasets. It is
also not completely clear if the previously mentioned diuretic
doses are the most appropriate to deﬁne reasonable baseline
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therapy. Future studies should examine the possibility of
using data acquired during a patient’s admission to hospital
to predict the likelihood that he or she will develop PRHF.
The consequences if PRHF develops should also be investi-
gated, and whether physicians can prevent PRHF or alter
the patient’s prognosis by managing differently those at risk.
Perhaps, intensive follow-up of these patients could mitigate
the risk of future adverse events? Ultimately, future studies
would need to determine whether there is a clinical beneﬁt
in diagnosing patients with PRHF.
Conclusions
Patients with in-hospital WHF are at greater risk of adverse
outcomes, including longer LOS, increased rate of
re-hospitalization, and higher mortality, compared with
patients who do not experience in-hospital WHF
(Figure 3),11,12,14,15,17,19,20,36,37and thus, in-hospital WHF is a
clinically important endpoint in patients with AHF. Despite
this, there is no universal, precise deﬁnition of in-hospital
WHF, which limits its value in deﬁning a population at risk
of poor outcomes, our ability to compare interventions, and
the widespread practical application of in-hospital WHF as
an endpoint. A reﬁned deﬁnition, which includes patients
who ‘fail to respond’ as well as those with worsening symp-
toms and signs, is needed. We hope that the consistent appli-
cation of PRHF in future clinical studies will help identify ‘at
risk’ patients, forming the basis for testing management
strategies directed at improving outcomes for these high-risk
patients.
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re-hospitalization, higher mortality rate, and greater economic burden.11,12,14,15,17,19,37
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